Episode 62: Josh Mandel-Brehm - CEO, CAMP4 Therapeutics

First In Human By Vial

Explore the untapped potential of RNA amplifying therapeutics with the CEO of CAMP4 Therapeutics, Josh Mandel-Brehm. We uncover the power of antisense oligonucleotides in rewriting the narrative for genetic diseases characterized by protein deficiency. Josh takes us behind the scenes of their innovative RNA Actuating Platform (RAP), a map charting the course of gene expression and a guide to the regulatory RNAs that can turn up the volume on genes gone silent due to disease. It's a pioneering journey through the promising avenues of metabolic disease treatment, with a special spotlight on their developmental star, CMP-CPS-001.
First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. View the full transcript here.
Interested in being featured as a guest on First In Human? Please reach out to [e-mail].
🎧 Stay in the Loop!
For the latest news and updates, visit our website: https://vial.com
Follow us on social media for real-time insights:
Twitter: https://twitter.com/VialTrials
LinkedIn: https://www.linkedin.com/company/vialtrials

Разделы

1. Episode 62: Josh Mandel-Brehm - CEO, CAMP4 Therapeutics (00:00:00)

2. Revolutionizing Treatments With RNA Therapeutics (00:00:06)

3. Exploring Dark Genome for Therapeutic Advances (00:11:31)

4. Partnerships for Drug Development Vision (00:19:10)